← All indications
Demyelinating Autoimmune Diseases, CNS
Conditions characterized by loss or dysfunction of myelin (see MYELIN SHEATH) in the brain, spinal cord, or optic nerves secondary to autoimmune mediated processes. This may take the form of a humoral or cellular immune response directed toward myelin or OLIGODENDROGLIA associated autoantigens.
Subtype terms (7)
More specific conditions that are subtypes of Demyelinating Autoimmune Diseases, CNS in the MeSH hierarchy.
- Diffuse Cerebral Sclerosis of Schilder
1 drug experimental
- Encephalomyelitis, Acute Disseminated
1 drug experimental
- Encephalomyelitis, Autoimmune, Experimental
- Multiple Sclerosis
396 drugs (204 approved, 192 experimental)
- Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease
- Myelitis, Transverse
9 drugs (5 approved, 4 experimental)
- Neuromyelitis Optica
65 drugs (35 approved, 30 experimental)
Drugs by status
Phase 4 trials (1)
Phase 3 trials (1)
Phase 2 trials (1)
Phase 1 trials (6)
Other trials (1)
Organizations
Organization Involved with Phase 4 Indications (3)